| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1244 | 2018 |
| Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group RKS Wong, RJ Bensadoun, CB Boers-Doets, J Bryce, A Chan, JB Epstein, ... Supportive Care in Cancer 21, 2933-2948, 2013 | 289 | 2013 |
| Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up DE Peterson, CB Boers-Doets, RJ Bensadoun, J Herrstedt Annals of Oncology 26, v139-v151, 2015 | 284 | 2015 |
| Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review CB Boers-Doets, JB Epstein, JE Raber-Durlacher, J Ouwerkerk, ... The oncologist 17 (1), 135-144, 2012 | 123 | 2012 |
| Mammalian target of rapamycin inhibitor-associated stomatitis CB Boers-Doets, JE Raber-Durlacher, NS Treister, JB Epstein, ... Future oncology 9 (12), 1883-1892, 2013 | 94 | 2013 |
| Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors Y Balagula, C Garbe, PL Myskowski, A Hauschild, BL Rapoport, ... International Journal of Dermatology 50 (2), 129-146, 2011 | 90 | 2011 |
| Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis LS Elting, YC Chang, P Parelkar, CB Boers-Doets, M Michelet, G Hita, ... Supportive Care in Cancer 21, 3243-3254, 2013 | 70 | 2013 |
| Prevention and management of adverse events related to regorafenib M De Wit, CB Boers-Doets, A Saettini, K Vermeersch, CR De Juan, ... Supportive Care in Cancer 22, 837-846, 2014 | 67 | 2014 |
| Xerosis and pruritus as major EGFRI-associated adverse events JMK Clabbers, CB Boers–Doets, H Gelderblom, T Stijnen, ME Lacouture, ... Supportive Care in Cancer 24, 513-521, 2016 | 58 | 2016 |
| Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer J Ouwerkerk, C Boers-Doets European Journal of Oncology Nursing 14 (4), 337-349, 2010 | 58 | 2010 |
| Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations … K Edmonds, D Hull, A Spencer-Shaw, J Koldenhof, M Chrysou, ... European Journal of Oncology Nursing 16 (2), 172-184, 2012 | 54 | 2012 |
| A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies A Chan, MC Cameron, B Garden, CB Boers-Doets, K Schindler, ... Supportive Care in Cancer 23, 2231-2244, 2015 | 35 | 2015 |
| ESMO Guidelines Committee Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up DE Peterson, CB Boers-Doets, RJ Bensadoun, J Herrstedt Ann Oncol 26 (Suppl 5), v139-v151, 2015 | 33 | 2015 |
| The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis CB Boers-Doets, RV Lalla Support Care Cancer 21 (S1), S140, 2013 | 27 | 2013 |
| Oral mucosal injury caused by targeted cancer therapies M Carrozzo, JG Eriksen, RJ Bensadoun, CB Boers-Doets, RV Lalla, ... JNCI Monographs 2019 (53), lgz012, 2019 | 24 | 2019 |
| Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international … T Behroozian, P Bonomo, P Patel, L Kanee, S Finkelstein, C van den Hurk, ... The Lancet Oncology 24 (4), e172-e185, 2023 | 23 | 2023 |
| Nasal vestibulitis due to targeted therapies in cancer patients JN Ruiz, VR Belum, CB Boers-Doets, M Kamboj, NE Babady, YW Tang, ... Supportive Care in Cancer 23, 2391-2398, 2015 | 23 | 2015 |
| Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events CB Boers-Doets, H Gelderblom, ME Lacouture, JB Epstein, JWR Nortier, ... Supportive Care in Cancer 21, 1919-1926, 2013 | 22 | 2013 |
| Non-rash dermatologic adverse events related to targeted therapies J Bryce, CB Boers-Doets Seminars in oncology nursing 30 (3), 155-168, 2014 | 15 | 2014 |
| Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch CB Boers-Doets, H Gelderblom, ME Lacouture, JM Bredle, JB Epstein, ... European Journal of Oncology Nursing 17 (6), 802-807, 2013 | 8 | 2013 |
Hans GelderblomLUMC在 lumc.nl 的电子邮件经过验证
